Zorn, Kevin, Bidair, Mohamed, Trainer, Andrew, Arther, Andrew, Kramolowsky, Eugene, Desai, Mihir, Doumanian, Leo, Elterman, Dean, Kaufman, Ronald, Lingeman, James, Krambeck, Amy, Eure, Gregg, Badlani, Gopal, Plante, Mark, Gin, Greg, Goldenberg, S, Paterson, Ryan, So, Alan, Humphreys, Mitchell, Roehrborn, Claus, Kaplan, Steven, Motola, Jay, Bhojani, Naeem, and Uchio, Edward
OBJECTIVE: The objective of this study is to determine if Aquablation therapy can maintain its effectiveness in treating men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with large-volume (80-150 cc) prostates at 3 years. SUBJECTS AND METHODS: One hundred one men with moderate-to-severe BPH symptoms and prostate volumes between 80 and 150 cc were enrolled in a prospective, nonrandomized, multicenter, international clinical trial in late 2017. Baseline, procedural, and follow-up parameters were recorded at baseline and scheduled postoperative visits. IPSS, Qmax, and treatment failure are reported at 3 years. RESULTS: The mean prostate volume was 107 cc (range 80-150). Mean IPSS improved from 23.2 at baseline to 6.5 at 3 years (16.3-point improvement, p